207 related articles for article (PubMed ID: 38315029)
1. Prevalence and variability of siderophore production in the
Sorlin P; Brivet E; Jean-Pierre V; Aujoulat F; Besse A; Dupont C; Chiron R; Jumas-Bilak E; Menetrey Q; Marchandin H
Microbiol Spectr; 2024 Mar; 12(3):e0295323. PubMed ID: 38315029
[No Abstract] [Full Text] [Related]
2. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.
Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H
Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850
[No Abstract] [Full Text] [Related]
3. Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates.
Amoureux L; Bador J; Bounoua Zouak F; Chapuis A; de Curraize C; Neuwirth C
J Cyst Fibros; 2016 Jul; 15(4):486-94. PubMed ID: 26778615
[TBL] [Abstract][Full Text] [Related]
4. Exoproducts of the Most Common
Sahl C; Baumgarten M; Shannon O; Påhlman LI
Microbiol Spectr; 2023 Aug; 11(4):e0019523. PubMed ID: 37284754
[No Abstract] [Full Text] [Related]
5. Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains.
Jean-Pierre V; Sorlin P; Pantel A; Chiron R; Lavigne JP; Jeannot K; Marchandin H;
Ann Clin Microbiol Antimicrob; 2024 Jun; 23(1):54. PubMed ID: 38886694
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the
Le Goff M; Vastel M; Lebrun R; Mansuelle P; Diarra A; Grandjean T; Triponney P; Imbert G; Gosset P; Dessein R; Garnier F; Durand E
Front Cell Infect Microbiol; 2022; 12():859181. PubMed ID: 35782124
[TBL] [Abstract][Full Text] [Related]
7. Achromobacter spp. prevalence and adaptation in cystic fibrosis lung infection.
Veschetti L; Boaretti M; Saitta GM; Passarelli Mantovani R; Lleò MM; Sandri A; Malerba G
Microbiol Res; 2022 Oct; 263():127140. PubMed ID: 35931003
[TBL] [Abstract][Full Text] [Related]
8. The
Pickrum AM; Riegert MO; Wells C; Brockman K; Frank DW
Microbiol Spectr; 2022 Aug; 10(4):e0208322. PubMed ID: 35856670
[TBL] [Abstract][Full Text] [Related]
9. Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.
Cools P; Ho E; Vranckx K; Schelstraete P; Wurth B; Franckx H; Ieven G; Van Simaey L; Van Daele S; Verhulst S; De Baets F; Vaneechoutte M
BMC Microbiol; 2016 Jun; 16(1):122. PubMed ID: 27342812
[TBL] [Abstract][Full Text] [Related]
10. Duplex real-time PCR assay for the simultaneous detection of
Price EP; Soler Arango V; Kidd TJ; Fraser TA; Nguyen TK; Bell SC; Sarovich DS
Microb Genom; 2020 Jul; 6(7):. PubMed ID: 32667877
[TBL] [Abstract][Full Text] [Related]
11. Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin.
Filipic B; Malesevic M; Vasiljevic Z; Lukic J; Novovic K; Kojic M; Jovcic B
Front Cell Infect Microbiol; 2017; 7():224. PubMed ID: 28611955
[No Abstract] [Full Text] [Related]
12.
Menetrey Q; Sorlin P; Jumas-Bilak E; Chiron R; Dupont C; Marchandin H
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919046
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant
Okoliegbe IN; Hijazi K; Cooper K; Ironside C; Gould IM
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816722
[No Abstract] [Full Text] [Related]
14. Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.
Pereira RH; Leão RS; Carvalho-Assef AP; Albano RM; Rodrigues ER; Firmida MC; Folescu TW; Plotkowski MC; Bernardo VG; Marques EA
Epidemiol Infect; 2017 Feb; 145(3):600-606. PubMed ID: 27873565
[TBL] [Abstract][Full Text] [Related]
15. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans.
Ridderberg W; Wang M; Nørskov-Lauritsen N
J Clin Microbiol; 2012 Aug; 50(8):2688-94. PubMed ID: 22675125
[TBL] [Abstract][Full Text] [Related]
16. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.
Magni A; Trancassini M; Varesi P; Iebba V; Curci A; Pecoraro C; Cimino G; Schippa S; Quattrucci S
J Clin Microbiol; 2010 Apr; 48(4):1035-9. PubMed ID: 20107101
[TBL] [Abstract][Full Text] [Related]
17. Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK.
Coward A; Kenna DT; Perry C; Martin K; Doumith M; Turton JF
J Cyst Fibros; 2016 Jul; 15(4):479-85. PubMed ID: 26412052
[TBL] [Abstract][Full Text] [Related]
18. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
Lobo LJ; Tulu Z; Aris RM; Noone PG
Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
[TBL] [Abstract][Full Text] [Related]
19. Presence of OXA-type enzymes in Achromobacter insuavis and A. dolens.
Traglia G; Papalia M; Almuzara M; Gutkind G; Centrón D; Vay C; Radice M; Ramírez MS
Curr Microbiol; 2014 Oct; 69(4):501-6. PubMed ID: 24894902
[TBL] [Abstract][Full Text] [Related]
20. Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137.
Amoureux L; Sauge J; Sarret B; Lhoumeau M; Bajard A; Tetu J; Bador J; Neuwirth C;
J Cyst Fibros; 2019 Nov; 18(6):804-807. PubMed ID: 31104975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
